The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•23 February 2026•

1 min read

Vanda Pharmaceuticals Surges 45% Following FDA Approval of BYSANTI

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Vanda Pharmaceuticals received FDA approval for BYSANTI (milsaperidone) to treat schizophrenia and bipolar I disorder.

2VNDA stock surged approximately 45% following the approval announcement.

Shares of Vanda Pharmaceuticals (VNDA) experienced a massive rally of approximately 45% following a major regulatory breakthrough. The U.S. Food and Drug Administration (FDA) granted approval for the company's new drug, BYSANTI, for the treatment of schizophrenia and bipolar I disorder. This approval serves as a significant fundamental catalyst for the biotech firm, which had previously been struggling with disappointing earnings reports. Notably, the drug has been granted "New Chemical Entity" (NCE) status, ensuring robust patent protection until 2044. Market observers suggest the sharp price increase may have been amplified by a potential short squeeze triggered by the positive news. While the long-term sustainability of the jump remains to be seen, the approval significantly strengthens Vanda's competitive position in the pharmaceutical market.